Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: 46,900 + web + cancer  Related to the article below (Last Update: 8/5/2008)


WELT ONLINE
Cardinal Reports Asset Quality Continues to Be Exceptional
WELT ONLINE, Germany - Jul 23, 2008
For additional information please visit our Web site at www.cardinalbank.com or call (703) 584-3400. Cardinal Financial Corporation and SubsidiariesSummary ...CFNL
Source: Google News

[PDF] … Accumulation of Polychlorinated Biphenyl Congeners in the Aquatic Food Web at the Kalamazoo River … -
DP Kay, AL Blankenship, KK Coady, AM Neigh, MJ … - Environmental Science & Technology, 2005 - usask.ca
... Polychlorinated Biphenyl Congeners in the Aquatic Food Web at the ... the PCB mixtures
were determined for various trophic positions within the aquatic food web. ...

[PDF] WMGMA Medicare/Medicaid Workgroup September 18, 2006
MB Clinic - wmgma.associationsonline.com
... recommends book marking the following CMS web address for ... may be covered under the
Colorectal Cancer Screening NCD ... area, versus the labial area 56501 or 46900? ...
-

Coding and billing for gastrointestinal endoscopy -
PL Stout - Gastrointestinal Endoscopy Clinics of North Americ, 2002 - Elsevier
... can be found on the AMA's web site:www ... Anoscopy 46600 through 46615 ? Destruction
46900 through 46942 ... G0104 colorectal cancer screening flexible sigmoidoscopy. ...

Pausing of reverse transcriptase on retroviral RNA templates is influenced by secondary structures … -
GP Harrison, MS Mayo, E Hunter, AM Lever - Nucleic Acids Research - Oxford Univ Press
... of Alabama at Birmingham, 845 19th Street South, Birmingham , AL 35294, USA , 1
Kansas Cancer Institute and ... Chem., December 6, 2002; 277(49): 46900 - 46911. ...

The SECs enforcement programme on biotechnologys communications with the investment community -
AS Gabinet - Journal of Commercial Biotechnology, 2006 - ingentaconnect.com
... not need to set out to deceive to find themselves with a tangled web of facts ... the
filing of its initial new drug application for an anti-cancer medicine, and ...
-

[PDF] Public Health Goal for 1, 1-Dichloroethylene In Drinking Water -
CEP Agency, GV Alexeeff - oehha.org
... Additional information on PHGs can be obtained at the OEHHA web site at www ... Proposition
65), as a chemical known to the state to cause cancer or reproductive ...

[PDF] Proposal for an Experiment at GSI, Darmstadt -
RIB Properties, E Equipment - gsi.helmholtz.de
Page 1. Date of Receipt: 31. August 2006 GSI Exp. No.: S319 Proposal for
an Experiment at GSI, Darmstadt Submit to: EA33 Title of ...

LC-MS ?????? -
??? - sigma-aldrich.co.jp
Page 1. Advances in Analytical Chemistry lssue 5?2007 ???
????????? ? ?????????? ??????? ...
-

Complementarity-directed RNA dimer-linkage promotes retroviral recombination in vivo -
JG Mikkelsen, SV Rasmussen, FS Pedersen - Nucleic Acids Research, 2004 - Oxford Univ Press
... This work was supported by the Danish Research Agency, the Bavarian Nordic Research
Institute, the Danish Cancer Society and the Karen Elise Jensen Foundation. ...

[BOOK] Dictionary of Carbohydrates with CD-ROM -
PM Collins - 2006 - books.google.com
... of Congress informa Visit the Taylor & Francis Web site at http://www.
taylorandfrancis.com and the CRC Press Web site at Taylor & ...

Source: Google Scholar

Viable Target For Drugs Holds Promise In The Treatment Of Cancers
By bypassing a well-known gene implicated in almost one-third of all cancers and instead focusing on the protein activated by the gene, Duke University Medical Center researchers believe they may have found a new target for anti-cancer drugs.

In experiments with human cells and animal models, the researchers studied the gene known as 'Ras,' which is integral in normal cell growth. When this gene is mutated and becomes overactive, it can lead to the unregulated proliferation of cells that is the hallmark of tumor formation.
The ras gene, known as an oncogene when it is in this mutated state, has been implicated in several different cancers, including those of the pancreas and lungs. To date, efforts at blocking or turning off ras have proven ineffective. Pancreatic cancer has been shown to have the strongest link to the ras oncogene, and it is also one of the hardest cancers to treat, with few patients alive five years after diagnosis, researchers said.

"Since it has been so difficult to target the ras gene itself with drugs, we tried to determine if something that ras activates could be a possible target for a drug or therapy," said Christopher Counter, Ph.D., associate professor of pharmacology and cancer biology and senior member of the research team. "We found a specific target that could be susceptible to drugs, and if these findings are proven true in human trials, we could have a new way of treating ras-dependent cancers."

The results of the Duke experiments were published July 15, 2007, in the journal Genes & Development. Brooke Ancrile, a graduate student in Counter's laboratory, was first author of the paper. The research was supported by the National Institutes of Health.

The researchers discovered that the overactive ras gene was responsible for above-normal secretion of a factor known as interleukin-6 (IL-6). Scientists know a great deal about IL-6 and its functions in the body, but its link to oncogenic ras was unknown.

In addition to finding that the ras oncogene spurred the production of IL-6, they also found that inhibiting IL-6 production reduced the creation of new blood vessels, which are crucial for the development and nourishment of tumors.

"IL-6 was like the gas pedal driving the growth of tumors," Counter said. "No gas, no growth, which is exactly what we saw when we inhibited IL-6 in tumors."

Counter is encouraged that even though these findings are in cell culture and animal models, therapies based on targeting IL-6 in cancers driven by the ras oncogene could be tested in humans in the near future. A biotechnology company has already developed a monoclonal antibody specific to IL-6 which could be used to neutralize IL-6.
A phase II trial is underway testing a monoclonal antibody against IL-6 for patients with multiple myeloma, a cancer that depends on IL-6 but is not known to have a connection to the ras oncogene. If the results of this trial are positive, studies might begin in ras-dependent cancers. Counter's group is actively pursuing the idea that such an antibody may inhibit pancreatic cancer growth in mouse models. If these results are positive, this will open the door for Duke oncologists to organize a clinical trial to test the agent in human cancer patients.

"Secreted proteins promoting the growth of blood vessels in tumors have been successfully neutralized in the past with antibodies," Ancrile said. "We believe that IL-6 is a viable target for drugs that holds promise in the treatment of cancers dependent on the ras oncogene."

Duke's Kian-Huat Lim was also a member of the research team.

Source: Richard Merritt
Duke University Medical Center
 
 
Google
Web www.iconocast.com

Search inside Iconocast for the keyword you have in mind.

Iconocast has collected more than 50,000 articles and press releases on health and science.

These are current and most up to date press releases on the subject you are searching.

We collect current health and science press releases daily from more than 5000 research and health institutes. Here is an example : The elderberry way to perfect skin

We believe if you do search inside Iconocast, you will get better results than searching the web alone.

 
 
Continue News With: News5 ; News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

Contact Iconocast

© 2003-07. ICONOCAST is a trademark of iconocast.com.